Conclusions
The presence of an ApoAI variant (AIMilano) in an Italian family leads to multiple lipid and lipoprotein abnormalities: a. markedly decreased HDL levels; b. hypertriglyceridemia resistant to diet and drug treatment; c. multiple structural and compositional abnormalities in the HDL fraction; d. absence of a significant incidence of atherosclerotic disease.
All these abnormalities are apparently linked to a single molecular defect conducing to dramatic changes in lipoprotein composition and metabolism. However, in the affected subjects no significant clinical abnormality may be detected. The AIMilano variant may possibly be considered as a ‘beneficial’ trait, exerting a protective role in the development of arterial disease.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Albers J. J., Wahl P. W., Cabana V. G., Hazzard W. R., Hoover J. J.: Quantitation of apolipoprotein AI of human plasma high density lipoprotein — Metabolism25, 633, 1976.
Fielding C. J., Shore V. G., Fielding P. E.: A protein cofactor of lecithin: cholesterol acyltransferase — Biochem. biophys. Res. Commun.46, 1493, 1972.
Franceschini G., Manzoni C., Frosi T., Sirtori C. R.: Heterogeneity of high density lipoproteins in patients with the AI-Milano variant. In: Lipoproteins and coronary atherosclerosis. Elsevier/North-Holland, Amsterdam. (In press).
Franceschini G., Sirtori C. R., Capurso A., Weisgraber K. H., Mahley R. W.: AI-Milano apoprotein. Decreased high density lipoprotein cholesterol levels with significant lipoprotein modifications and without clinical atherosclerosis in an Italian family — J. clin. Invest.66, 892, 1980.
Franceschini G., Sirtori M., Gianfranceschi G., Sirtori C. R.: Relation between the HDL apoproteins and AI isoproteins in subjects with the AI-Milano abnormality — Metabolism30, 502, 1981.
Gordon T., Castelli W., Hjörtland M., Kannel W. B., Dawber T.: High density lipoproteins as a protective factor against coronary heart disease — Amer. J. Med.62, 707, 1977.
Miller G. J., Miller N. E.: Plasma high density lipoprotein concentration and development of ischemic heart disease — Lanceti, 16, 1975.
Miller N. E., Nestel P. J., Clifton-Bligh P.: Relationships between plasma lipoprotein cholesterol concentrations and the pool size and metabolism of cholesterol in man — Atherosclerosis23, 535, 1976.
Morrisett J. D., Jackson R. L., Gotto A. M. Jr.: Lipid-protein interactions in the plasma lipoproteins — Biochim. biophys. Acta (Amst.)472, 93, 1977.
Rhoads G., Gulbrandsen C. L., Kagan A.: Serum lipoproteins and coronary heart disease in a population study of Hawaii Japanese men — New Engl. J. Med.294, 293, 1976.
Stein Y., Glangeaud M. C., Fainaru M., Stein O.: The removal of cholesterol from aortic smooth muscle cells in culture and Landschutz ascites cells by fractions of human high density lipoproteins — Biochim. biophys. Acta (Amst.)380, 106, 1975.
Van Tornout P., Caster H., Levens M. J., Rosseneu M., Assmann G.:In vitro interaction of human HDL with human apolipoprotein AII — Biochim. biophys. Acta (Amst.)663, 630, 1980.
Weisgraber K. H., Bersot T. P., Mahley R. W., Franceschini G., Sirtori C. R.: AI-Milano apoprotein. Isolation and characterization of a cysteine-containing variant of the AI apoprotein from human high density lipoproteins — J. clin. Invest.66, 901, 1980.
Weisgraber K. H., Mahley R. W.: Subfractionation of human high density lipoproteins by heparin-sepharose affinity chromatography — J. Lipid Res.21, 316, 1980.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Sirtori, C.R., Franceschini, G. Apolipoprotein AIMilano . La Ricerca Clin. Lab. 12, 83–86 (1982). https://doi.org/10.1007/BF02909311
Issue Date:
DOI: https://doi.org/10.1007/BF02909311